WO2007030619A3 - Pharmaceutical compositions for delivery of ribonucleic acid to a cell - Google Patents

Pharmaceutical compositions for delivery of ribonucleic acid to a cell Download PDF

Info

Publication number
WO2007030619A3
WO2007030619A3 PCT/US2006/034859 US2006034859W WO2007030619A3 WO 2007030619 A3 WO2007030619 A3 WO 2007030619A3 US 2006034859 W US2006034859 W US 2006034859W WO 2007030619 A3 WO2007030619 A3 WO 2007030619A3
Authority
WO
WIPO (PCT)
Prior art keywords
delivery
cell
pharmaceutical compositions
ribonucleic acid
dsrna
Prior art date
Application number
PCT/US2006/034859
Other languages
French (fr)
Other versions
WO2007030619A2 (en
Inventor
Kunyuan Cui
Michael E Houston Jr
Lishan Chen
Sasha J Mayer
Yuching Chen
Original Assignee
Nastech Pharm Co
Kunyuan Cui
Michael E Houston Jr
Lishan Chen
Sasha J Mayer
Yuching Chen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/223,699 external-priority patent/US20060035815A1/en
Application filed by Nastech Pharm Co, Kunyuan Cui, Michael E Houston Jr, Lishan Chen, Sasha J Mayer, Yuching Chen filed Critical Nastech Pharm Co
Priority to CA002621694A priority Critical patent/CA2621694A1/en
Priority to EP06803119A priority patent/EP1934359A2/en
Priority to JP2008530199A priority patent/JP2009507852A/en
Priority to AU2006287481A priority patent/AU2006287481A1/en
Publication of WO2007030619A2 publication Critical patent/WO2007030619A2/en
Publication of WO2007030619A3 publication Critical patent/WO2007030619A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A composition, method for causing uptake in animal cells of double stranded RNA (dsRNA) and reduction of a target mRNA and a use of a mixture for the production of a medicament for the treatment for Tumor Necrosis Factor-alpha (TNF-α) associated inflammatory condition(s) in an animal subject comprising a polynucleotide delivery-enhancing polypeptide and a dsRNA, wherein the polynucleotide delivery-enhancing polypeptide is amphipathic and comprises nucleic acid binding properties are described.
PCT/US2006/034859 2005-09-08 2006-09-08 Pharmaceutical compositions for delivery of ribonucleic acid to a cell WO2007030619A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002621694A CA2621694A1 (en) 2005-09-08 2006-09-08 Pharmaceutical compositions for delivery of ribonucleic acid to a cell
EP06803119A EP1934359A2 (en) 2005-09-08 2006-09-08 Pharmaceutical compositions for delivery of ribonucleic acid to a cell
JP2008530199A JP2009507852A (en) 2005-09-08 2006-09-08 Pharmaceutical composition for delivery of ribonucleic acid to cells
AU2006287481A AU2006287481A1 (en) 2005-09-08 2006-09-08 Pharmaceutical compositions for delivery of ribonucleic acid to a cell

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US11/223,699 2005-09-08
US11/223,699 US20060035815A1 (en) 2004-05-04 2005-09-08 Pharmaceutical compositions for delivery of ribonucleic acid to a cell
US72721605P 2005-10-14 2005-10-14
US60/727,216 2005-10-14
US73366405P 2005-11-04 2005-11-04
US60/733,664 2005-11-04

Publications (2)

Publication Number Publication Date
WO2007030619A2 WO2007030619A2 (en) 2007-03-15
WO2007030619A3 true WO2007030619A3 (en) 2007-10-04

Family

ID=37836462

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/034859 WO2007030619A2 (en) 2005-09-08 2006-09-08 Pharmaceutical compositions for delivery of ribonucleic acid to a cell

Country Status (5)

Country Link
EP (1) EP1934359A2 (en)
JP (1) JP2009507852A (en)
AU (1) AU2006287481A1 (en)
CA (1) CA2621694A1 (en)
WO (1) WO2007030619A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8921314B2 (en) 2008-10-15 2014-12-30 Angiochem, Inc. Conjugates of GLP-1 agonists and uses thereof
US8969310B2 (en) 2005-07-15 2015-03-03 Angiochem Inc. Potentiation of anticancer agents
US9161988B2 (en) 2009-07-02 2015-10-20 Angiochem Inc. Multimeric peptide conjugates and uses thereof
US9173891B2 (en) 2009-04-20 2015-11-03 Angiochem, Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
US9221867B2 (en) 2003-01-06 2015-12-29 Angiochem Inc. Method for transporting a compound across the blood-brain barrier
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060040882A1 (en) * 2004-05-04 2006-02-23 Lishan Chen Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
CA2597958C (en) 2005-02-18 2019-01-15 Angiochem Inc. Molecules for transporting a compound across the blood-brain barrier
EP2056845B1 (en) 2006-08-08 2017-10-11 Rheinische Friedrich-Wilhelms-Universität Bonn Structure and use of 5' phosphate oligonucleotides
US20080076701A1 (en) * 2006-08-18 2008-03-27 Nastech Pharmaceutical Company Inc. Dicer substrate rna peptide conjugates and methods for rna therapeutics
MX2010006925A (en) * 2007-12-20 2011-05-02 Angiochem Inc Polypeptide-nucleic acid conjugates and uses thereof.
US9040492B2 (en) 2008-03-31 2015-05-26 National Institute Of Advanced Industrial Science And Technology Double-stranded lipid-modified RNA having high RNA interference effect
JP5689413B2 (en) 2008-05-21 2015-03-25 ライニッシュ フリードリッヒ−ウィルヘルムズ−ユニバーシタット ボン 5 'triphosphate oligonucleotide having blunt ends and uses thereof
CN102307904A (en) 2008-12-05 2012-01-04 安吉奥开米公司 Conjugates of neurotensin or neurotensin analogs and uses thereof
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
WO2013103899A2 (en) * 2012-01-06 2013-07-11 H. Lee Moffitt Cancer Center And Research Institute Phosphorylation of histones and uses thereof
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
ES2826827T3 (en) 2015-06-15 2021-05-19 Angiochem Inc Methods for the treatment of leptomeningeal carcinomatosis
CN114259460B (en) * 2020-09-16 2024-03-15 苏州大学 Hydrogel composition based on immunoadjuvant and application thereof
CN114632161B (en) * 2020-12-16 2024-02-06 中国人民解放军军事科学院军事医学研究院 Application of tumor necrosis factor-alpha as nucleic acid gene medicine in-vivo delivery carrier

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679559A (en) * 1996-07-03 1997-10-21 University Of Utah Research Foundation Cationic polymer and lipoprotein-containing system for gene delivery
WO2001081370A2 (en) * 2000-04-24 2001-11-01 Novartis Ag Histone h2a-derived peptides useful in gene delivery
WO2004087931A1 (en) * 2003-04-03 2004-10-14 Korea Advanced Institute Of Science And Technology Conjugate for gene transfer comprising oligonucleotide and hydrophilic polymer, polyelectrolyte complex micelles formed from the conjugate, and methods for preparation thereof
US20050147993A1 (en) * 2003-10-24 2005-07-07 Shaharyar Khan Methods and compositions for delivering polynucleotides
WO2005117991A2 (en) * 2004-05-04 2005-12-15 Nastech Pharmaceutical Company Inc. Compositions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589503B1 (en) * 1998-06-20 2003-07-08 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
AU2003217550A1 (en) * 2002-02-20 2003-09-09 Ribozyme Pharmaceuticals, Incorporated RNA INTERFERENCE MEDIATED INHIBITION OF TNF AND TNF RECEPTOR SUPERFAMILY GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679559A (en) * 1996-07-03 1997-10-21 University Of Utah Research Foundation Cationic polymer and lipoprotein-containing system for gene delivery
WO2001081370A2 (en) * 2000-04-24 2001-11-01 Novartis Ag Histone h2a-derived peptides useful in gene delivery
WO2004087931A1 (en) * 2003-04-03 2004-10-14 Korea Advanced Institute Of Science And Technology Conjugate for gene transfer comprising oligonucleotide and hydrophilic polymer, polyelectrolyte complex micelles formed from the conjugate, and methods for preparation thereof
US20050147993A1 (en) * 2003-10-24 2005-07-07 Shaharyar Khan Methods and compositions for delivering polynucleotides
WO2005117991A2 (en) * 2004-05-04 2005-12-15 Nastech Pharmaceutical Company Inc. Compositions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE GENESEQ E.B.I. Hinxton U.K.; 14 February 2002 (2002-02-14), BALICKI D AND BEUTLER E: "Histone 2A-derived gene delivery peptide #15", XP002431354, Database accession no. AAU70895 *
JOHNSON P.H.: "Development of Therapeutic siRNAs against TNF-alpha and Novel Peptide Delivery Agents for the Treatment of Rheumatoid Arthritis", 13 June 2005 (2005-06-13), XP002431337, Retrieved from the Internet <URL:http://www.nastech.com/pdf/RNAi_Conference%20Presentation_CHI_061305.pdf> [retrieved on 20070425] *
PUEBLA I ET AL: "A RECOMBINANT H1 HISTONE-BASED SYSTEM FOR EFFICIENT DELIVERY OF NUCLEIC ACIDS", JOURNAL OF BIOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 105, no. 3, 2003, pages 215 - 226, XP009057520, ISSN: 0168-1656 *
SIMEONI F ET AL: "Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 31, no. 11, 13 March 2003 (2003-03-13), pages 2717 - 2724, XP002984580, ISSN: 0305-1048 *
WITKOWSKA RENATA T ET AL: "Peptide-mediated delivery of siRNA via noncovalent complexes and covalent conjugates", June 2005 (2005-06-01), 19TH AMERICAN PEPTIDE SYMPOSIUM; SAN DIEGO, CA, USA; JUNE 18 -23, 2005, XP002431336, Retrieved from the Internet <URL:http://www.nastech.com/pdf/nastech_APS_062005.pdf> [retrieved on 20070425] *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9221867B2 (en) 2003-01-06 2015-12-29 Angiochem Inc. Method for transporting a compound across the blood-brain barrier
US8969310B2 (en) 2005-07-15 2015-03-03 Angiochem Inc. Potentiation of anticancer agents
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
US8921314B2 (en) 2008-10-15 2014-12-30 Angiochem, Inc. Conjugates of GLP-1 agonists and uses thereof
US9173891B2 (en) 2009-04-20 2015-11-03 Angiochem, Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
US9161988B2 (en) 2009-07-02 2015-10-20 Angiochem Inc. Multimeric peptide conjugates and uses thereof

Also Published As

Publication number Publication date
WO2007030619A2 (en) 2007-03-15
EP1934359A2 (en) 2008-06-25
JP2009507852A (en) 2009-02-26
AU2006287481A1 (en) 2007-03-15
CA2621694A1 (en) 2007-03-15

Similar Documents

Publication Publication Date Title
WO2007030619A3 (en) Pharmaceutical compositions for delivery of ribonucleic acid to a cell
NZ553828A (en) Method of treating an inflammatory disease by double stranded ribonucleic acid by inhibiting TNF-alpha
WO2008118212A3 (en) In vivo delivery of double stranded rna to a target cell
WO2005060697A3 (en) Cell transfecting formulations of small interfering rna, related compositions and methods of making and use
UA101155C2 (en) Modified polypeptide of factor vii (fvii) and its using
CA2782676C (en) Pharmaceutical compositions for intracellular delivery of nucleic acids and proteins and uses thereof for treatment of ureca cycle metabolic disorders
WO2006034433A3 (en) Delivery of polynucleotides
WO2012075040A3 (en) mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
WO2011091307A8 (en) Affinity hydrogels for controlled protein release
WO2006018836A3 (en) Nucleic acid constructs and cells, and methods utilizing same for modifying the electrophysiological function of excitable tissues
WO2007118245A8 (en) Methods and compositions related to adenoassociated virus-phage particles
WO2012024396A3 (en) Compositions and methods for delivering nucleic acid molecules and treating cancer
WO2006081008A3 (en) Nucleic acids for apoptosis of cancer cells
WO2008033285A3 (en) Delivery of double-stranded rna into the central nervous system
WO2011133960A9 (en) Lysosomal storage disease enzyme
WO2009135165A3 (en) Small humanin-like peptides
WO2013096958A8 (en) Compositions and methods for the delivery of biologically active rnas
WO2009086428A3 (en) Methods and compositions for increasing gene expression
WO2009059201A3 (en) Id2 as a target in colorectal carcinoma
TW200806302A (en) Short interference ribonucleic acids for treating allergic dieases
WO2005067632A3 (en) Lipid compositions and use thereof
WO2006071884A3 (en) Oligonucleotide based therapeutics
WO2011054939A3 (en) Compositions and methods for inhibiting expression of kif10 genes
WO2011139842A3 (en) Nucleic acid compounds for inhibiting fgfr3 gene expression and uses thereof
Gasparian et al. Purification of high-quality RNA from synthetic polyethylene glycol-based hydrogels

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680033090.8

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2008530199

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2621694

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006287481

Country of ref document: AU

Ref document number: 566526

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/003380

Country of ref document: MX

Ref document number: 2057/DELNP/2008

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006803119

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006272483

Country of ref document: AU

Date of ref document: 20060908

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020087008482

Country of ref document: KR

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06803119

Country of ref document: EP

Kind code of ref document: A2